Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus (Q36715772)

15 August 2017

1 reference

title

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus (English)

1 reference

15 August 2017

1 reference

1 reference

1

Tina Vilsbøll

1 reference

PubMed ID

17243943

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

1 reference

15 August 2017

16

1 reference

15 August 2017

2

1 reference

15 August 2017

231-237

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

New sources of pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Rapid gastric emptying of a solid pancake meal in type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Ileal release of glucagon-like peptide-1 (GLP-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.231

10.1517/13543784.16.2.231

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17243943